Anrotinib Combined With Tirelizumab in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Had histopathologically confirmed nonkeratinizing recurrent/metastatic NPC (AJCC, 8th; the metastatic tissue biopsy is preferred, not necessary; locoregional recurrent lesion unfit for local treatment).
• Subjects enrolled must have measurable lesion(s) according to response evaluation criteria in solid (RECIST) v1.1.
• ECOG performance status of 0～2
• Life expectancy more than 12 weeks.
• unable or unwilling to undergo chemothraphy
• Able to understand and sign an informed consent form (ICF).
Locations
Other Locations
China
Zhongshan City People's Hospital
RECRUITING
Zhongshan
Contact Information
Primary
Guiqiong Xu, MD
donna_shee@163.com
+8613528109888
Time Frame
Start Date: 2023-06-01
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 27
Treatments
Experimental: Anrotinib plus Tirelizumab arm
Subjects receive anrotinib plus tirelizumab
Related Therapeutic Areas
Sponsors
Leads: Zhongshan People's Hospital, Guangdong, China